Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
AIM ImmunoTech Inc (AIM) Insider Trading Activity
Healthcare • Biotechnology • 26 employees
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Total Value
$226,036.73
Total Shares
922,909
Average Trade Value
$9,418.20
Most Active Insider
Equels Thomas K
Total Activity: $144,512
Largest Single Transaction
$100,000
by Equels Thomas K on Sep 11, 2024
30-Day Activity
2 Transactions
Volume: 51,594 shares
Value: $10,417
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director
|
Jan 31, 2025 | 25,797 | $5,208 | 198,063 (+13.0%) | Grant | |
|
Director
|
Jan 31, 2025 | 25,797 | $5,208 | 165,073 (+15.6%) | Grant | |
|
Director
|
Jan 15, 2025 | 27,412 | $5,208 | 172,226 (+15.9%) | Grant | |
|
Director
|
Jan 15, 2025 | 27,412 | $5,208 | 139,276 (+19.7%) | Grant | |
|
Director
|
Dec 31, 2024 | 26,305 | $5,208 | 111,864 (+23.5%) | Grant | |
|
Director
|
Dec 31, 2024 | 8,768 | $1,736 | 388,729 (+2.3%) | Grant | |
|
Director
|
Dec 31, 2024 | 26,305 | $5,208 | 144,854 (+18.2%) | Grant | |
|
Director
|
Dec 19, 2024 | 4,580 | $884 | 118,549 (-3.9%) | Sale | |
|
CEO President
Director, Officer
|
Dec 18, 2024 | 22,727 | $4,682 | 1,680,695 (+1.4%) | Purchase | |
|
Director
|
Dec 13, 2024 | 24,452 | $5,208 | 85,559 (+28.6%) | Grant | |
|
Director
|
Dec 13, 2024 | 24,452 | $5,208 | 379,961 (+6.4%) | Grant | |
|
Director
|
Dec 13, 2024 | 24,452 | $5,208 | 123,803 (+19.8%) | Grant | |
|
Director
|
Dec 2, 2024 | 22,645 | $5,208 | 344,397 (+6.6%) | Grant | |
|
Director
|
Dec 2, 2024 | 11,111 | $2,356 | 355,509 (+3.1%) | Purchase | |
|
Director
|
Dec 2, 2024 | 1 | $0 | 344,398 (+0.0%) | Purchase | |
|
Director
|
Dec 2, 2024 | 22,645 | $5,208 | 99,351 (+22.8%) | Grant | |
|
Director
|
Dec 2, 2024 | 22,645 | $5,208 | 61,107 (+37.1%) | Grant | |
|
CEO President
Director, Officer
|
Nov 21, 2024 | 20,000 | $4,240 | 1,657,968 (+1.2%) | Purchase | |
|
CEO President
Director, Officer
|
Nov 20, 2024 | 60,110 | $11,000 | 1,552,968 (+3.9%) | Purchase | |
|
CEO President
Director, Officer
|
Nov 20, 2024 | 85,000 | $16,915 | 1,637,968 (+5.2%) | Purchase | |
|
Director
|
Nov 20, 2024 | 81,953 | $15,817 | 321,752 (+25.5%) | Purchase | |
|
CEO President
Director, Officer
|
Sep 16, 2024 | 5,000 | $1,515 | 1,493,042 (+0.3%) | Purchase | |
|
CEO President
Director, Officer
|
Sep 13, 2024 | 20,000 | $6,160 | 1,488,042 (+1.3%) | Purchase | |
|
CEO President
Director, Officer
|
Sep 11, 2024 | 312,500 | $100,000 | 1,468,042 (+21.3%) | Grant |